Published in Women's Health Weekly, April 21st, 2011
Tamoxifen USA publicized today another breakthrough for the research chemical sector. Tamoxifen is an antagonist of the oestrogen receptor in breast tissue as a result of its active metabolite, hydroxytamoxifen. In different tissues such as the endometrium, it behaves as an agonist, hence tamoxifen may be portrayed as a combined agonist/antagonist. It has been the conventional hormonal (anti-estrogen) therapy for hormone receptor-positive early breast cancer in pre-menopausal women, although aromatase inhibitors have been recommended.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly